Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

Drug Interactions With Direct-Acting Antivirals for Hepatitis C

(2015) Sarah Burgess et al.   ANNALS OF PHARMACOTHERAPY

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations

(2014) Clara T. M. M. de Kanter et al.   CLINICAL PHARMACOKINETICS

Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz

(2014) Panjasaram Naidoo et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

(2014) Xavier Forns et al.   GASTROENTEROLOGY

P1319 ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL

(2014) C. Moreno et al.   JOURNAL OF HEPATOLOGY

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

(2014) Ira M Jacobson et al.   LANCET

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Michael Manns et al.   LANCET

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

(2014) Eric Lawitz et al.   LANCET

Potential statin-drug interactions: prevalence and clinical significance

(2014) Maria Zhelyazkova-Savova et al.   SpringerPlus

Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors

(2013) Benoit Chauvin et al.   CLINICAL PHARMACOKINETICS

Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate

(2013) P. N. Morcos et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial

(2013) Stefan Zeuzem et al.   GASTROENTEROLOGY

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

(2013) Michael W. Fried et al.   HEPATOLOGY

Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting

(2013) Sarah Tischer et al.   JOURNAL OF HEPATOLOGY

Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice

(2012) John W. Ward et al.   CLINICAL INFECTIOUS DISEASES

Update on rifampin, rifabutin, and rifapentine drug interactions

(2012) Anne M. Baciewicz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions

(2011) Min-Koo Choi et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Clinically Significant Drug Interactions with Newer Antidepressants

(2011) Edoardo Spina et al.   CNS DRUGS

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

(2010) Alexander Jetter et al.   ANTIVIRAL THERAPY

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: I. Evidence Against CYP3A Mediation of Methadone Clearance

(2008) ED Kharasch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone

(2008) Tuomas Korhonen et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

(2008) Laura Dickinson et al.   Current Opinion in HIV and AIDS